BridgeBio Oncology Therapeutics, Inc. (BBOT)
NASDAQ: BBOT · Real-Time Price · USD
8.74
-0.44 (-4.79%)
At close: Aug 28, 2026, 4:00 PM EDT
8.91
+0.17 (1.95%)
After-hours: Aug 28, 2026, 7:30 PM EDT
BBOT Stock Forecast
Stock Price Forecast
According to 11 analysts polled by S&P Global, BBOT stock has a consensus rating of "Strong Buy" and an average price target of $24.9. The average 1-year stock price forecast is 184.90% higher than the current stock price, while the lowest is $18 (+105.95%) and the highest is $39 (+346.22%).
Price Target: $24.9 (+184.90%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for BBOT stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Mar '26 | Apr '26 | May '26 | Jun '26 | Jul '26 | Aug '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 6 | 7 | 7 | 7 | 7 |
| Buy | 3 | 3 | 3 | 3 | 4 | 4 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 9 | 9 | 10 | 10 | 11 | 11 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Morgan Stanley | Morgan Stanley | Buy Reiterates $18 | Buy | Reiterates | $18 | +105.95% | Aug 17, 2026 |
| J.P. Morgan | J.P. Morgan | Buy Reiterates $27 → $25 | Buy | Reiterates | $27 → $25 | +186.04% | Aug 14, 2026 |
Unknown Analyst Wedbush No rating | Wedbush | Buy Initiates $25 | Buy | Initiates | $25 | +186.04% | Aug 12, 2026 |
| Oppenheimer | Oppenheimer | Buy Reiterates $22 | Buy | Reiterates | $22 | +151.72% | Aug 12, 2026 |
| Canaccord Genuity | Canaccord Genuity | Buy Reiterates $23 | Buy | Reiterates | $23 | +163.16% | Aug 12, 2026 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-2.68
from -4.30
EPS Next Year
-2.41
from -2.68
EPS and Forward PE are based on non-GAAP adjusted numbers.